CMPX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Compass Therapeutics Inc. (CMPX) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. Despite short-term price declines, the stock has strong long-term growth potential due to its promising pipeline, positive analyst ratings, and upcoming catalysts like Phase 2/3 data and potential FDA filings. The technical indicators and options data also suggest a neutral to slightly bullish sentiment.
The MACD histogram is positive at 0.0131 and expanding, indicating a potential bullish trend. RSI at 48.194 is neutral, and moving averages are converging, suggesting no clear trend. Key support is at 4.978, and resistance is at 5.589. The stock is currently trading near its pivot point of 5.283.
Analysts have initiated coverage with Buy ratings and price targets as high as $15, citing a deep pipeline and promising lead asset Tovecimig.
Upcoming Phase 2/3 data and potential FDA filings for Tovecimig in Q1
High probability of significant price appreciation in the next month based on candlestick pattern analysis.
Recent price decline of -2.91% in the regular market and additional losses in pre-market and post-market trading.
Weak financial performance in Q4 2025, including negative net income and declining EPS.
In Q4 2025, revenue remained at $0, net income improved slightly to -$15.7M (up 4.54% YoY), but EPS dropped by -27.27% YoY to -0.08. Gross margin was 0, indicating no profitability.
Analysts are bullish on CMPX, with multiple Buy ratings and price targets ranging from $13 to $15. They highlight the company's innovative pipeline, particularly Tovecimig, which has shown promising results in clinical trials and could achieve $1B in peak sales upon commercialization.
